E J Small
Affiliation: University of California
- Second-line hormonal therapy for advanced prostate cancer: a shifting paradigmE J Small
Department of Medicine, University of California, San Francisco 94115, USA
J Clin Oncol 15:382-8. 1997..To discuss the evolution of new concepts in the Use of second-line hormonal therapy for patients with progressive prostate cancer despite androgen deprivation...
- Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisoneE J Small
University of California at San Francisco Comprehensive Cancer Center, San Francisco 94115, USA
J Clin Oncol 18:1440-50. 2000..A prospective randomized clinical trial was designed to evaluate pain and opioid analgesic intake as surrogates for antitumor response in HRPC patients with significant, opioid analgesic-dependent pain...
- Androgen deprivation therapy for patients with clinically localized (stages T1 to T3) prostate cancer and for patients with biochemical recurrence after radical prostatectomyG D Grossfeld
Department of Urology, University of California, San Francisco/Mount Zion Cancer Center, San Francisco, California 94143-0738, USA
Urology 58:56-64. 2001..The role of ADT in patients with clinically localized and recurrent prostate cancer, whether it is delivered in a continuous or intermittent fashion, must be determined in randomized, prospective trials...
- Intermittent androgen deprivation: update of cycling characteristics in patients without clinically apparent metastatic prostate cancerG D Grossfeld
Department of Urology, University of California, San Francisco, School of Medicine, San Francisco, California 94143-0738, USA
Urology 58:240-5. 2001..Longer follow-up with more patients failing IAD will be required before clear patterns of failure emerge in these patients...
- Pyrazoloacridine for the treatment of hormone-refractory prostate cancerE J Small
Department of Medicine, University of California, San Francisco, USA
Cancer Invest 16:456-61. 1998..If PSA is used as a marker of response, single-agent PZA appears to lack efficacy in the treatment of HRPC. However, the one unambiguous response, and the favorable toxicity profile observed, may warrant further evaluation of this agent...
- New treatment strategies in advanced prostate cancerE J Small
Department of Medicine, University of California San Francisco, USA
Radiol Clin North Am 38:203-11, ix-x. 2000....
- HER2 protein expression and gene amplification in androgen-independent prostate cancerD M Reese
Urologic Oncology Program, Division of Hematology-Oncology, Comprehensive Cancer Center, University of California, 2356 Sutter St, 5th Floor, San Francisco, CA 94115, USA
Am J Clin Pathol 116:234-9. 2001..Two (6%) of 36 specimens had gene amplification by FISH. These data suggest that HER2 protein overexpression and gene amplification are relatively uncommon in AIPC...
- Serum prostate-specific antigen decline as a marker of clinical outcome in hormone-refractory prostate cancer patients: association with progression-free survival, pain end points, and survivalE J Small
University of California, San Francisco, CA, USA
J Clin Oncol 19:1304-11. 2001..The purpose of this study was to determine whether posttreatment declines in PSA were associated with clinical measures of improvement in a randomized phase III trial of suramin plus hydrocortisone versus placebo plus hydrocortisone...
- Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancerW K Kelly
Genitourinary Oncology Service, Division of Solid Tumor, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021 6007, USA
J Clin Oncol 19:44-53. 2001..To determine the safety and activity of weekly paclitaxel in combination with estramustine and carboplatin (TEC) in patients with advanced prostate cancer...
- Therapy of advanced prostate cancer with granulocyte macrophage colony-stimulating factorE J Small
Department of Medicine, University of California, San Francisco 94115, USA
Clin Cancer Res 5:1738-44. 1999....
- Androgen deprivation therapy in locally advanced and metastatic prostate cancerC J Ryan
Department of Medicine and UCSF Comprehensive Cancer Center, University of California, San Francisco, CA 94143, USA
Minerva Urol Nefrol 58:119-26. 2006..In virtually all analyses, patients with high-risk features benefited from early AD when compared to deferred therapy. Consideration of AD is therefore warranted early in the clinical course of high-risk patients...
- Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cellsE J Small
Department of Medicine and Urology, University of California San Francisco Comprehensive Cancer Center, University of California, San Francisco, CA 94115, USA
J Clin Oncol 18:3894-903. 2000..Sequential phase I and phase II trials were performed to determine the safety and efficacy of Provenge and to assess its capacity to break immune tolerance to the normal tissue antigen PAP...
- Secondary hormonal manipulation of prostate cancerK A Harris
University of California, San Francisco Comprehensive Cancer Center, 1600 Divisadero Street, 3rd Floor, San Francisco, CA 94115, USA
Curr Urol Rep 2:224-30. 2001..This approach is predicated on the recognition that HRPC is a heterogeneous disease, and some patients may respond to alternative hormonal interventions despite the presence of castrate levels of testosterone...
- An update on prostate cancer researchE J Small
University of California, San Francisco, Comprehensive Cancer Center, 94115, USA
Curr Opin Oncol 12:265-72. 2000..Finally, treatment strategies for patients with androgen-independent disease have also expanded, although novel therapies are required to improve survival in this group of patients...
- Docetaxel, estramustine, plus trastuzumab in patients with metastatic androgen-independent prostate cancerE J Small
Urologic Oncology Program, University of California, San Francisco Comprehensive Cancer Center, San Francisco, CA 94143-1711, USA
Semin Oncol 28:71-6. 2001..The response data are too preliminary for speculation about the relative benefits of this 3-drug regimen compared with the combination of only docetaxel and estramustine in this clinical setting...
- Inhibition of the androgen receptor by mineralocorticoids at levels physiologically achieved in serum in patients treated with abiraterone acetateW Kim
Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA
Prostate Cancer Prostatic Dis 17:292-9. 2014..The aim of this study was to elucidate the biological significance of elevated mineralocorticoid levels on androgen receptor (AR) activity in prostate cancer (PC) cells...
- Phase II study of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma: CALGB 90207J E Rosenberg
Division of Hematology and Oncology, University of California, San Francisco Cancer Center, San Francisco, CA 94115, USA
Ann Oncol 19:946-50. 2008..Response rates to second-line chemotherapy for advanced UC are low and response duration is short. Bortezomib is a proteasome inhibitor with preclinical activity against UC...
- The evolving role of androgen deprivation therapy in the management of prostate cancerM R Cooperberg
Department of Urology, UCSF Mt Zion Comprehensive, Cancer Center, University of California, San Francisco, CA 94115 1711, USA
Minerva Urol Nefrol 55:219-38. 2003..Finally, contemporary practice pattern data suggest that use of ADT is increasing across patient risk groups, both in contexts where such therapy is well supported by current evidence and in others where it is not...
- Selection for androgen receptor mutations in prostate cancers treated with androgen antagonistM E Taplin
University of Massachusetts Cancer Center, Worcester 01655, USA
Cancer Res 59:2511-5. 1999..These findings demonstrate that AR mutations occur in response to strong selective pressure from flutamide treatment...
- Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480D J George
Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA
Clin Cancer Res 7:1932-6. 2001..CONCLUSION: Although these data are exploratory and need to be confirmed in an independent data set, they suggest that VEGF may have clinical significance in patients with HRPC...
- A multi-institutional phase ii study of SU101, a platelet-derived growth factor receptor inhibitor, for patients with hormone-refractory prostate cancerY J Ko
Beth Israel Deaconess Medical Center, Harvard Medical School Boston, Massachusetts 02215, USA
Clin Cancer Res 7:800-5. 2001..PDGF-r expression was detected in 80% of the metastases and 88% of primary prostate cancers. The results of this trial may warrant further clinical studies with other PDGF-r inhibitors...
- Hormonal treatment for prostate cancerK A Harris
UCSF Comprehensive Cancer Center, 1600 Divisadero Street, 3rd Floor, San Francisco, CA 94115, USA
Expert Opin Investig Drugs 10:493-510. 2001..It has been hoped that the development of alternative hormonal interventions might lead to both enhanced antitumour efficacy as well as improvements in side effect profile...
- Independent association of angiogenesis index with outcome in prostate cancerR Mehta
Oncotech Incorporated, Irvine, California 92614, USA
Clin Cancer Res 7:81-8. 2001..Further validation of the angiogenesis index in prostate carcinoma may provide a new tool to stratify patient risk...